Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity
Anthracyclines are one of the most effective chemotherapy agents and have revolutionized cancer therapy. However, anthracyclines can induce cardiac injuries through ‘multiple-hits', a series of cardiovascular insults coupled with lifestyle risk factors, which increase the risk of developing sho...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.805735/full |
| _version_ | 1828133854470209536 |
|---|---|
| author | Dong-Woo Kang Dong-Woo Kang Rebekah L. Wilson Rebekah L. Wilson Cami N. Christopher Cami N. Christopher Amber J. Normann Amber J. Normann Oscar Barnes Jordan D. Lesansee Gyuhwan Choi Christina M. Dieli-Conwright Christina M. Dieli-Conwright |
| author_facet | Dong-Woo Kang Dong-Woo Kang Rebekah L. Wilson Rebekah L. Wilson Cami N. Christopher Cami N. Christopher Amber J. Normann Amber J. Normann Oscar Barnes Jordan D. Lesansee Gyuhwan Choi Christina M. Dieli-Conwright Christina M. Dieli-Conwright |
| author_sort | Dong-Woo Kang |
| collection | DOAJ |
| description | Anthracyclines are one of the most effective chemotherapy agents and have revolutionized cancer therapy. However, anthracyclines can induce cardiac injuries through ‘multiple-hits', a series of cardiovascular insults coupled with lifestyle risk factors, which increase the risk of developing short- and long-term cardiac dysfunction and cardiovascular disease that potentially lead to premature mortality following cancer remission. Therefore, the management of anthracycline-induced cardiotoxicity is a serious unmet clinical need. Exercise therapy, as a non-pharmacological intervention, stimulates numerous biochemical and physiologic adaptations, including cardioprotective effects, through the cardiovascular system and cardiac muscles, where exercise has been proposed to be an effective clinical approach that can protect or reverse the cardiotoxicity from anthracyclines. Many preclinical and clinical trials demonstrate the potential impacts of exercise on cardiotoxicity; however, the underlying mechanisms as well as how to implement exercise in clinical settings to improve or protect against long-term cardiovascular disease outcomes are not clearly defined. In this review, we summarize the current evidence in the field of “exercise cardio-oncology” and emphasize the utilization of exercise to prevent and manage anthracycline-induced cardiotoxicities across high-risk and vulnerable populations diagnosed with cancer. |
| first_indexed | 2024-04-11T17:25:33Z |
| format | Article |
| id | doaj.art-4a7100e9117e4bda8e5f22efec73df13 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-11T17:25:33Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-4a7100e9117e4bda8e5f22efec73df132022-12-22T04:12:20ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-01-01810.3389/fcvm.2021.805735805735Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced CardiotoxicityDong-Woo Kang0Dong-Woo Kang1Rebekah L. Wilson2Rebekah L. Wilson3Cami N. Christopher4Cami N. Christopher5Amber J. Normann6Amber J. Normann7Oscar Barnes8Jordan D. Lesansee9Gyuhwan Choi10Christina M. Dieli-Conwright11Christina M. Dieli-Conwright12Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesDepartment of Medicine, Harvard Medical School, Boston, MA, United StatesDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesDepartment of Medicine, Harvard Medical School, Boston, MA, United StatesDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesDepartment of Epidemiology, School of Public Health, Boston University, Boston, MA, United StatesDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesDepartment of Health Sciences, Boston University, Boston, MA, United StatesGreen Templeton College, University of Oxford, Oxford, United KingdomDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, United StatesYale University, New Haven, CT, United StatesDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesDepartment of Medicine, Harvard Medical School, Boston, MA, United StatesAnthracyclines are one of the most effective chemotherapy agents and have revolutionized cancer therapy. However, anthracyclines can induce cardiac injuries through ‘multiple-hits', a series of cardiovascular insults coupled with lifestyle risk factors, which increase the risk of developing short- and long-term cardiac dysfunction and cardiovascular disease that potentially lead to premature mortality following cancer remission. Therefore, the management of anthracycline-induced cardiotoxicity is a serious unmet clinical need. Exercise therapy, as a non-pharmacological intervention, stimulates numerous biochemical and physiologic adaptations, including cardioprotective effects, through the cardiovascular system and cardiac muscles, where exercise has been proposed to be an effective clinical approach that can protect or reverse the cardiotoxicity from anthracyclines. Many preclinical and clinical trials demonstrate the potential impacts of exercise on cardiotoxicity; however, the underlying mechanisms as well as how to implement exercise in clinical settings to improve or protect against long-term cardiovascular disease outcomes are not clearly defined. In this review, we summarize the current evidence in the field of “exercise cardio-oncology” and emphasize the utilization of exercise to prevent and manage anthracycline-induced cardiotoxicities across high-risk and vulnerable populations diagnosed with cancer.https://www.frontiersin.org/articles/10.3389/fcvm.2021.805735/fullcardio-oncologyexercisecardiotoxicityanthracyclinescancer survivorsexercise cardio-oncology |
| spellingShingle | Dong-Woo Kang Dong-Woo Kang Rebekah L. Wilson Rebekah L. Wilson Cami N. Christopher Cami N. Christopher Amber J. Normann Amber J. Normann Oscar Barnes Jordan D. Lesansee Gyuhwan Choi Christina M. Dieli-Conwright Christina M. Dieli-Conwright Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity Frontiers in Cardiovascular Medicine cardio-oncology exercise cardiotoxicity anthracyclines cancer survivors exercise cardio-oncology |
| title | Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity |
| title_full | Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity |
| title_fullStr | Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity |
| title_full_unstemmed | Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity |
| title_short | Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity |
| title_sort | exercise cardio oncology exercise as a potential therapeutic modality in the management of anthracycline induced cardiotoxicity |
| topic | cardio-oncology exercise cardiotoxicity anthracyclines cancer survivors exercise cardio-oncology |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.805735/full |
| work_keys_str_mv | AT dongwookang exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT dongwookang exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT rebekahlwilson exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT rebekahlwilson exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT caminchristopher exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT caminchristopher exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT amberjnormann exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT amberjnormann exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT oscarbarnes exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT jordandlesansee exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT gyuhwanchoi exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT christinamdieliconwright exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity AT christinamdieliconwright exercisecardiooncologyexerciseasapotentialtherapeuticmodalityinthemanagementofanthracyclineinducedcardiotoxicity |